Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Crawford Amrein, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Venkataraman V, Casey KS, Onozato M, Cin PD, Nardi V, Amrein PC, Bergeron MK, Brunner AM, Fathi AT, Foster JE, Moran J, Graubert TA, Hock H, Hunnewell C, Frigault MJ, McAfee S, Hobbs GS. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia. 2020 Jul 16. PMID: 32678290.
    Citations:    
  2. Flügge T, Ludwig U, Winter G, Amrein P, Kernen F, Nelson K. Fully guided implant surgery using Magnetic Resonance Imaging - An in vitro study on accuracy in human mandibles. Clin Oral Implants Res. 2020 Aug; 31(8):737-746. PMID: 32459868.
    Citations:    
  3. Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 Jan 14; 4(1):106-111. PMID: 31905241.
    Citations:    
  4. Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2020 Mar 15; 126(6):1264-1273. PMID: 31860140.
    Citations:    
  5. Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133. PMID: 31837959.
    Citations:    
  6. Jia F, Elshatlawy H, Aghaeifar A, Chu YH, Hsu YC, Littin S, Kroboth S, Yu H, Amrein P, Gao X, Yang W, LeVan P, Scheffler K, Zaitsev M. Design of a shim coil array matched to the human brain anatomy. Magn Reson Med. 2020 04; 83(4):1442-1457. PMID: 31565814.
    Citations:    
  7. Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852. PMID: 31299106.
    Citations:    
  8. Chen EC, Werner L, Hobbs GS, Narayan R, Amrein PC, Fathi AT, Brunner AM. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leuk Lymphoma. 2019 12; 60(12):3058-3062. PMID: 31120366.
    Citations:    
  9. Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938. PMID: 31074316.
    Citations:    
  10. Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203. PMID: 30926081.
    Citations:    
  11. El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402. PMID: 30923318.
    Citations:    
  12. Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549. PMID: 30422308.
    Citations:    Fields:    
  13. El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, Hobbs G, Foster J, Brunner A, Amrein P, Stone RM, Temel JS. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254. PMID: 30139841.
    Citations:    Fields:    
  14. DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261. PMID: 29119643.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  15. Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2018 01; 81(1):217-222. PMID: 29119293.
    Citations:    Fields:    
  16. Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040. PMID: 29296849.
    Citations: 1     
  17. Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018 01 15; 124(2):306-314. PMID: 28960265.
    Citations: 1     Fields:    
  18. Jalbut MM, Brunner AM, Amrein PC, Ballen KK, Hobbs GS, Perry AM, Joseph CP, Fathi AT. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):988-991. PMID: 28792269.
    Citations:    Fields:    Translation:HumansCells
  19. Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK, Neuberg DS, Fathi AT. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer. 2017 Jul 01; 123(13):2561-2569. PMID: 28464280.
    Citations:    Fields:    Translation:Humans
  20. Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 04; 102(4):719-727. PMID: 28034990.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  21. El-Jawahri A, Keenan T, Abel GA, Steensma DP, LeBlanc TW, Chen YB, Hobbs G, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Ballen KK, Amrein PC, Stone RM, Temel JS. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83. PMID: 27264037.
    Citations:    Fields:    Translation:Humans
  22. Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, Attar EC, Steensma DP, Wadleigh M, Foster J, Connolly C, Galinsky I, Devoe CE, Stone RM, Neuberg DS, Ballen KK. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88. PMID: 27171984.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  23. Keenan T, Abel GA, Steensma DP, LeBlanc TW, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs G, Amrein PC, Stone RM, Ballen KK, Chen YA, Temel JS. Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206. PMID: 28148109.
    Citations:    
  24. El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, DeAngelo DJ, Wadleigh M, Ballen KK, Foster JE, Attar EC, Amrein PC, Brunner AM, Stone RM, Temel JS. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8. PMID: 25926135.
    Citations: 8     Fields:    Translation:Humans
  25. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989. PMID: 25723171.
    Citations: 64     Fields:    Translation:HumansCells
  26. Movassaghian M, Brunner AM, Blonquist TM, Sadrzadeh H, Bhatia A, Perry AM, Attar EC, Amrein PC, Ballen KK, Neuberg DS, Fathi AT. Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. Leuk Lymphoma. 2015 Jun; 56(6):1698-703. PMID: 25213180.
    Citations: 9     Fields:    Translation:Humans
  27. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. PMID: 25079173.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  28. Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res. 2014 Jul; 38(7):773-80. PMID: 24793731.
    Citations: 2     Fields:    Translation:HumansCells
  29. Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014 Mar 01; 28(5):479-90. PMID: 24589777.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  30. Deangelo DJ, Neuberg D, Amrein PC, Berchuck J, Wadleigh M, Sirulnik LA, Galinsky I, Golub T, Stegmaier K, Stone RM. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4. PMID: 24522247.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  31. Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20. PMID: 23773898.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  32. Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Neuberg DS, Fathi AT. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013 Aug; 88(8):642-6. PMID: 23619915.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  33. Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM, Ballen KK, Amrein PC, Maciejewski J, Attar EC. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117. PMID: 23708642.
    Citations: 3     Fields:    
  34. Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9. PMID: 23129738.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  35. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52. PMID: 23074281.
    Citations: 32     Fields:    Translation:HumansCells
  36. Fathi AT, Preffer FI, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, McAfee SL, Dillon L, Chen YB, Hasserjian RP. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma. 2013 Apr; 54(4):860-3. PMID: 22966913.
    Citations: 5     Fields:    Translation:HumansCells
  37. Singh H, Werner LL, Asali S, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Wolpin B, Pidala J, Neuberg DS, Fox EA, Stone RM, Attar EC. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7. PMID: 21681787.
    Citations: 2     Fields:    Translation:Humans
  38. Singh H, Asali S, Werner LL, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Neuberg DS, Fox EA, Stone RM, Attar EC. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5. PMID: 21696826.
    Citations: 3     Fields:    Translation:HumansCells
  39. Amrein PC. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leuk Lymphoma. 2011 May; 52(5):754-63. PMID: 21463117.
    Citations: 8     Fields:    Translation:Humans
  40. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011 May 01; 17(9):2977-86. PMID: 21402714.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  41. Poitras JL, Costa D, Kluk MJ, Amrein PC, Stone RM, Lee C, Dal Cin P, Morton CC. Genomic alterations in myeloid neoplasms with novel, apparently balanced translocations. Cancer Genet. 2011 Feb; 204(2):68-76. PMID: 21504705.
    Citations: 2     Fields:    Translation:Humans
  42. Singh H, Werner L, Deangelo D, Ballen K, Amrein P, Wadleigh M, Neuberg D, Fox E, Stone R, Attar E. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7. PMID: 20981678.
    Citations: 2     Fields:    Translation:HumansCells
  43. Farris AB, Hasserjian RP, Zukerberg LR, Amrein PC, Greene RE, Mark EJ, Kradin RL. Diffuse cellular and fibrosing interstitial pneumonitis with desquamative interstitial pneumonitis-like features associated with myeloid neoplasia. Am J Surg Pathol. 2009 Oct; 33(10):1485-93. PMID: 19654503.
    Citations: 1     Fields:    Translation:Humans
  44. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54. PMID: 18316568.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  45. Meyer GS, Hales CA, Amrein PC, Sharma A, Kradin RL. Case records of the Massachusetts General Hospital. Case 26-2007 - a 61-year-old man with recurrent fevers. N Engl J Med. 2007 Aug 23; 357(8):807-16. PMID: 17715414.
    Citations: 4     Fields:    Translation:Humans
  46. Chung RT, Iafrate AJ, Amrein PC, Sahani DV, Misdraji J. Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. N Engl J Med. 2006 May 18; 354(20):2166-75. PMID: 16707754.
    Citations: 8     Fields:    Translation:Humans
  47. Moore SD, Offor O, Ferry JA, Amrein PC, Morton CC, Dal Cin P. ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22). Leuk Res. 2006 Aug; 30(8):1037-42. PMID: 16303180.
    Citations: 8     Fields:    Translation:HumansCells
  48. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer. 2005 Oct 01; 104(7):1418-27. PMID: 16116597.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  49. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 01; 105(9):3420-7. PMID: 15572587.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  50. Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res. 2004 Apr 01; 10(7):2222-30. PMID: 15073096.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  51. Penson RT, Amrein PC. Faith and freedom: leukemia in Jehovah Witness minors. Onkologie. 2004 Apr; 27(2):126-8. PMID: 15138343.
    Citations: 1     Fields:    Translation:Humans
  52. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 01; 10(3):944-6. PMID: 14871971.
    Citations: 38     Fields:    Translation:HumansCTClinical Trials
  53. Dal Cin P, Sherman L, Marzelli M, McLaughlin C, Zukerberg L, Amrein PC. A new case of t(11;17)(q23;q21) with MLL rearrangement. Cancer Genet Cytogenet. 2004 Jan 15; 148(2):178-9. PMID: 14734237.
    Citations: 1     Fields:    Translation:HumansCells
  54. Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003 Nov 01; 9(14):5178-86. PMID: 14613997.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  55. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003 Oct; 39(7):724-7. PMID: 12907212.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  56. Deangelo D, Liu D, Stone R, Amrein PC, Schiffer C, Tallman M, Fernandez H, Leopold L, Berger M. Preliminary report of a phase 2 study of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin in patients <60 years of age with de novo acute myeloid leukemia. ASCO. 2003; (#2325).
  57. Amrein P, Soulieres D, Schab A, Lipscher E, Pearce L, Besterman J, Nimmrich I, Reid G, Burger M. Effect of MG98 treatment on DNA gene promoter CpG island methylation patterns in advanced head and neck carcinoma patients. ASCO. 2003; (#830).
  58. WangL, Zukerberg L, Ferry JA, Tang Z, Amrein P, Harris N. Chronic myelogenous leukemia with Gleevec/ST1571 treatment leads to a rapid hematological but slower cytogenetic response. USCAP. 2003; (#1175).
  59. DeAngelo D, Soiffer R, Galinsky I, Clark J, Gilliland DG, Shanahan J, Amrein PC. Stone R. Imatinib Mesylate (Gleevecâ) for patients with chronic idiopathic myelofibrosis (CIM): A phase II trial. ASH. 2003.
  60. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J, Rosenthal S, Joseph M, Amrein P. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002 May 15; 94(10):2623-34. PMID: 12173330.
    Citations: 29     Fields:    Translation:Humans
  61. Glisson B, Colevas AD, Krane J, El-Nagger A, Costello R, Summey C, Lake-Willcut B, Arguette M, Langer C, Amrein P, Posner M. Over-expression of HER2/NEU in carcinomas of the salivary gland: Dependence on histologic subtyp. AACR. 2002; (#1120).
  62. Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT. Faith, identity, and leukemia: when blood products are not an option. Oncologist. 2002; 7(4):371-80. PMID: 12185299.
    Citations: 1     Fields:    Translation:Humans
  63. Amrein PC, Puchalski T, Supko J, Ryan D, Clark JW, Castellana W, Garcia-Carbonero R, Eder JP Jr. Phase I Clinical and Pharmacokinetic Study of 1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea in Patients with Refractory Solid Tumors. ASCO. 2002; 78b (#2123).
  64. Amrein P, Clark JR, Wang CC, Varvares M, Deschler D, Rocco J, Fabian R, McIntyre J. Phase I/II study of paclitaxel in combination with amifostine and twice daily radiotherapy for advanced head and neck cancer. Sixth Research Workshop on the Biology, Prevention and Treatment of Head and Neck Cancer. 2002; (#084).
  65. DeAngelo D, Schiffer C, Amrein P. Interim analysis of a phase II study of the safety and efficacy of gentuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia. ASH. 2002.
  66. Guilhot F, Bouabdullah R, Desaklins B, Michallet, Ferrat A, Chopra R, Amrein PC, Camlett I, Ross G, Saba H. Topotecan, cytosine arabinoside and G-CSF (TAG) versus idarabicin, cytosine arabinoside and G-CSF (IDAG) in patients with myelodysplastic syndrome (MDS) or MDS in transformation: A randomized Phase III Study. ASH. 2002.
  67. Colevas AD, Amrein PC, Gomolin H, Barton JJ, Read RR, Adak S, Benner S, Costello R, Posner MR. A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer. 2001 Jul 15; 92(2):326-31. PMID: 11466686.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  68. Amrein P.C., Supko J.G., Puchalski T.A., Colevas A.D., Wang C.C., Varvares M., Fabian R., McIntyre J. Phase I and Pharmacokinetic (PK) Study of Paclitaxel in Combination with Amifostine During Radiotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck. ASCO. 2001; 236 (#940).
  69. Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Posner MR. A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann Oncol. 2000 May; 11(5):535-9. PMID: 10907945.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  70. Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer. 2000 May 01; 88(9):2037-41. PMID: 10813714.
    Citations: 1     Fields:    Translation:Humans
  71. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5. PMID: 10753831.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  72. Stone RM, Larson RA, Miller K, Moore JO, Amrein PC, Karp JE, Antin JH, Zani VJ, Schiffer CA. A Randomized, placebo-controlled double-blind trial of a loading dose of pegylated recombinant human megakaryocytic growth and development factor (MGDF) as an adjunct to chemotherapy for acute myeloid leukemia (AML). ASCO. 2000; 6 (#14).
  73. Amrein PC, McIntyre J, Colevas AD, Wang CC, Varvares M, Fabian R. A phase I Trial of concurrent Taxol and BID radiotherapy with and without Ethyol in patients with advanced squamous cell carcinoma of the head and neck. ASCO. 2000; 418 (#1651).
  74. Read R, Gomolin H, Amrein P, Norris C, Costello R, Barton J, Benner S, Posner M, Colevas AD. A phase II study of oral uracil and ftorafur (UFT) plus leucovorin (ORZEL) in advanced local-regional or metastatic squamous cell carcinoma of the head and neck (SCCHN). ASCO. 2000; 420 (#1661).
  75. Ryan DP, Eder JP, Supko JG, Lynch TJ, Amrein PC, Fuchs CS, Roper K, Washington T, Sonnichsen D, Tuck D, Clark JW. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors. ASCO. 2000; 185 (#720).
  76. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999 Nov; 17(11):3503-11. PMID: 10550148.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  77. Colevas AD, Gomolin HI, Amrein PC, Costello R, Read R, Posner, MR. Oral Uracil and Ftorafur (UFT) plus Leucovorin (ORZEL) in advanced local-regional or metastatic squamous cell carcinoma of the head and neck (SCCHN). ASCO. 1999; 404 (#1561).
  78. Amrein PC, Wang CC, McIntyre j, Varvares M, Fabian R. Preliminary report of a phase I trial of concurrent Taxol and BID radiotherapy in patients with advanced stage squamous cell carcinoma of the head and neck. ASCO. 1999; 403 (#1556).
  79. Weissgold DJ, Gragoudas ES, Kent C, Amrein PC, Dickersin GR. Choroidal metastasis from olfactory neuroblastoma (esthesioneuroblastoma). Retina. 1999; 19(5):459-62. PMID: 10546948.
    Citations:    Fields:    Translation:Humans
  80. Lee EJ, George SL, Amrein PC, Paciucci PA, Allen SL, Schiffer CA. An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B. Leukemia. 1998 Feb; 12(2):139-43. PMID: 9519774.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  81. Colevas AD, Busse PM, Norris CM, Fried MP, Tishler RB, Poulin M, Costello R, Gomolin H, Amrein PC, Barton JJ, Posner MR. Phase II TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN). ASCO. 1998; 383 (#1474).
  82. Blobe GC and Amrein PC. The P53 Tumor Suppressor Gene in Head and Neck Cancer . Current Opinion in Otolaryngology and Head and Neck Surgery. 1998; 6:129-133.
  83. Amrein PC, Wang CC, Daly M, McIntyre J, Fabian R. Concurrent Taxol and BID radiotherapy in patients with advanced stage squamous cell carcinoma of the head and neck. ASCO. 1998; 402 (#1548).
  84. Thornton AF, Varvares M, McIntyre J, Fabian R, Amrein PC. Treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. ASCO. 1998; 411 (#1585).
  85. Schiffer Ca, Miller K, Larson RA, Stone R, Amrein PC, Antin. A double blind, placebo controlled trial evaluating pegylated recombinant human megakaryocyte growth and development factor (MGDF) as an adjunct to induction and consolidation therapy in patients with acute myeloid leukemia (AML). ASH. 1998; 313 (#1283).
  86. Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, Godfrey S, Robert F, Schiffer CA. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997 Feb 01; 89(3):780-8. PMID: 9028308.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  87. Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997 Jan; 123(1):34-40. PMID: 9006501.
    Citations: 18     Fields:    Translation:Humans
  88. Amrein PC, Colecchi CH, Finkelstein DM, Fabian RL. Adjuvant Chemotherapy in Advanced Head and Neck Cancer. Oncologist. 1997; 2(3):135-141. PMID: 10388043.
    Citations: 1     Fields:    
  89. Bhattacharyya N, Joseph MP, Goodman ML, Thornton AF, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: results in nine cases. 4th International Conf. Head Neck Cancer. 1996; 210 (#567).
  90. Amrein PC, Colecchi C, Fabian R. Adjuvant chemotherapy in patients with high-risk squamous cell carcinoma of the head and neck. ASCO. 1996; 15: 318 (#901).
  91. Amrein PC. Chemotherapy in head and neck cancer. Oxford Textbook of Surgery . 1994.
  92. Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer. 1993 Apr 01; 71(7):2326-31. PMID: 8453554.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  93. Amrein PC, Fabian RL. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate. Laryngoscope. 1992 Aug; 102(8):901-6. PMID: 1379664.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  94. Gerard EL, Ferry JA, Amrein PC, Harmon DC, McKinstry RC, Hoppel BE, Rosen BR. Compositional changes in vertebral bone marrow during treatment for acute leukemia: assessment with quantitative chemical shift imaging. Radiology. 1992 Apr; 183(1):39-46. PMID: 1549692.
    Citations: 6     Fields:    Translation:Humans
  95. Lee EJ, Amrein PC, Paciucci PA, Schiffer CA. Haematology and Blood Transfusion: CALGB Studies in Relapsed AML. In: Acute Leukemias-Pharmacokinetics - Pharmacokinetics and Management of Relapsed and Refractory Disease. Berlin Heidelberg: Springer-Verlag. 1992; 388-391.
  96. Moore JD, Schiffer CA, Amrein PC, Dodge R. G-CSF dramatically reduces the duration of both granulocytopenia and thrombocytopenia after AZQ/mitoxantrone consolidation in acute myelogenous leukemia. ASH. 1992; 291a (#1156).
  97. Amrein P. Current chemotherapy of head and neck cancer. J Oral Maxillofac Surg. 1991 Aug; 49(8):864-70. PMID: 2072199.
    Citations:    Fields:    Translation:Humans
  98. Urba S, Forastiere AA, Amrein PC. A phase II pilot study of concomitantly administered recumbinant human interleukin-2 and Roferon-A in patients with locally recurrent or metastatic head and neck cancer. ASCO. 1991; 10: 208 (#695).
  99. Amrein PC, Davis RB, Mayer RJ, Schiffer CA. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Am J Hematol. 1990 Oct; 35(2):80-3. PMID: 2399909.
    Citations: 3     Fields:    Translation:Humans
  100. Amrein PC. Cisplatin and 5-FU vs. the same plus bleomycin and methotrexate in recurrent squamous cell carcinoma of the head and neck. ASCO. 1990; 9: 175 (#676).
  101. Lee EJ, Paciucci A, Amrein PC, Schulman P, Davis R, Schiffer C. A randomized phase II trial of 3 regimens in the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults: A CALGB study. ASH. 1990; 294a (#1166).
  102. Piro AJ, Amrein PC, Pietrafitta JJ. Cancer of the Esophagus. Chapter 19 in Osteen, RT: Cancer Manual. Eighth Edition, American Cancer Societ . 1990.
  103. Amrein PC. Case records of the Massachusetts General Hospital, "66 year old woman with Waldenstrom's macroglobulinemia, diarrhea, and bleeding" . N Eng J Med . 1990; 322:183-192.
  104. McFarland EL, McKinstry R, Ferry J, Amrein, PC. Bone marrow changes during treatment for acute leukemia: assessment with quantitative MRI chemical shift imaging. Radiol Soc of N Amer. 1989.
  105. Amrein PC. ombination Diaziquoue and Mitoxantrone for patients with relapsed or refractory acute non-lymphocytic leukemia. ASCO. 1988; 7: 183 (#523).
  106. Amrein PC. Case records of the Massachusetts General Hospital, "47 year old white male with colon cancer and leukemia" . N Eng J Med. 1988; 319:356-364.
  107. Amrein PC. Preliminary results of a trial comparing cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate in recurrent squamous cell carcinoma of the head and neck. ASCO. 1987; 6: 133 (C-523).
  108. Rybak ME, Anderson JR, Poulin RF, Amrein PC, Canellos GP, Gottlieb AJ. Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972. Cancer Treat Rep. 1986 Oct; 70(10):1233-4. PMID: 3530451.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  109. Ellis FH, Amrein PC, Piro AJ. Carcinoma of the Esophagus. Chapter 16 in Cady B Cancer Manual. Seventh Edition, American Cancer Society . 1986.
  110. Amrein PC, Weitzman SA. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol. 1985 Dec; 3(12):1632-9. PMID: 2415693.
    Citations: 18     Fields:    Translation:Humans
  111. Amrein PC, Weitzman SA. 24-hour infusion cisplatinum and 5-day infusion of 5-fluorouracil in squamous cell carcinoma of the head and neck. ASCO. 1985; 4: 133 (C-519).
  112. Amrein PC, Coleman M, Richards F, Bhardwaj S, Kennedy BJ, Haurani FI, Frelick RW, Pastmantier MW, Herschkopf R. Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and leukemia group B phase II study. Cancer Treat Rep. 1984 Nov; 68(11):1397-8. PMID: 6548660.
    Citations:    Fields:    Translation:Humans
  113. Amrein PC, Poulin RF, Coleman M, Richards F, Weil M, Kennedy BJ, Carey RW, Green MR, Holland JF, Weinberg V, et al. The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study. Am J Clin Oncol. 1984 Jun; 7(3):269-71. PMID: 6547269.
    Citations:    Fields:    Translation:Humans
  114. Amrein PC, Richards F, Coleman M, Poulin RF, Holland JF, Weinberg V, Perry M. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1984 Jun; 68(6):923-4. PMID: 6329510.
    Citations: 1     Fields:    Translation:Humans
  115. Amrein PC, Coleman M, Richards F, Poulin RF, Berkowitz I, Kennedy BJ, Green M, Herschkopf R, Rafla S. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1983 Nov; 67(11):1043-4. PMID: 6688967.
    Citations:    Fields:    Translation:Humans
  116. Amrein PC, Fingert H, Weitzman SA. Cisplatin-vincristine-bleomycin therapy in squamous cell carcinoma of the head and neck. J Clin Oncol. 1983 Jul; 1(7):421-7. PMID: 6199477.
    Citations: 3     Fields:    Translation:Humans
  117. Niederman R, Amrein PC, Hartwig J. Three-dimensional structure of actin filaments and of an actin gel made with actin-binding protein. J Cell Biol. 1983 May; 96(5):1400-13. PMID: 6682423.
    Citations: 22     Fields:    Translation:AnimalsCells
  118. Amrein PC, Weitzman SA. 24-hour infusion cis-platinum, vincristine, bleomycin therapy in squamous cell carcinoma of the head and neck. ASCO. 1983; 2:158 (C-617).
  119. Amrein PC. Case records of the Massachusetts General Hospital, "24 year old white male with pancytopenia and fever" . N Eng J Med. 1983; 308:1081-1091.
  120. Amrein PC, Kumar JR, Poulin RF, Umlas J, Weitzman SA. Comparison of filtration leukapheresis and centrifugation leukapheresis in treatment of lymphosarcoma cell leukemia. South Med J. 1982 Aug; 75(8):969-71. PMID: 7112205.
    Citations:    Fields:    Translation:HumansCells
  121. Amrein PC, Coleman M, Richards F, Poulin RF, Bernhardt B, Ginsberg SJ, Green MR, Morrison A, Cortes E, Kiang D, Weinberg V, Wood WC. Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982 May; 66(5):1211-3. PMID: 6896294.
    Citations: 1     Fields:    Translation:Humans
  122. Amrein PC, Ellman L, Harris WH. Aspirin-induced prolongation of bleeding time and perioperative blood loss. JAMA. 1981 May 08; 245(18):1825-8. PMID: 7014935.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  123. Amrein PC, Stossel TP. Prevention of degradation of human polymorphonuclear leukocyte proteins by diisopropylfluorophosphate. Blood. 1980 Sep; 56(3):442-7. PMID: 6773606.
    Citations: 44     Fields:    Translation:HumansCells
  124. Amrein PC, Friedman R, Kosinski K, Ellman L. Hematologic changes in anorexia nervosa. JAMA. 1979 May 18; 241(20):2190-1. PMID: 219270.
    Citations: 2     Fields:    Translation:HumansCells
  125. Amrein P, Ellman L. Sézary syndrome with warm and cold erythrocyte autoantibodies. Blood. 1978 Jun; 51(6):1229-30. PMID: 148302.
    Citations:    Fields:    Translation:HumansCells
  126. Amrein PC, Larson SM, Wagner HN. A rapid automated system for measurement of antibody titers. J Nucl Med. 1974 Dec; 15(12):1145-8. PMID: 4610098.
    Citations: 1     Fields:    Translation:Cells
  127. Amrein PC, Larson SM, Wagner HN. An automated system for measurement of leukocyte metabolism. J Nucl Med. 1974 May; 15(5):352-5. PMID: 4823269.
    Citations: 5     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Amrein's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (386)
Explore
_
Co-Authors (109)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.